Literature DB >> 23078061

Hepatitis C virus recurrence and immunosuppression-free state after liver transplantation.

Tommaso Maria Manzia1, Roberta Angelico, Luca Toti, Quirino Lai, Paolo Ciano, Mario Angelico, Giuseppe Tisone.   

Abstract

HCV-related disease is the most common indication for liver transplantation (LT). HCV recurrence, which is almost universal, has a significant impact on patient and graft survival after LT and still represents a great unsolved issue for the liver transplant community. Several treatment strategies have been proposed. Since antiviral therapy has limited efficacy and can be administrated only in selected transplant recipients and additionally that immunosuppressive drugs have a negative impact on HCV re-infection, the achievement of an immunosuppression-free state after LT could play a central role in the avoidance of rapid HCV recurrence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23078061     DOI: 10.1586/eci.12.66

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  3 in total

1.  Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients.

Authors:  Tommaso Maria Manzia; Roberta Angelico; Paolo Ciano; Jon Mugweru; Kofi Owusu; Daniele Sforza; Luca Toti; Giuseppe Tisone
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 2.  Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.

Authors:  Alberto Grassi; Giorgio Ballardini
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

3.  De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature.

Authors:  Tommaso Maria Manzia; Roberta Angelico; Carlo Gazia; Ilaria Lenci; Martina Milana; Oludamilola T Ademoyero; Domiziana Pedini; Luca Toti; Marco Spada; Giuseppe Tisone; Leonardo Baiocchi
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.